Driehaus Capital Management Reduces $7M in Spyre Therapeutics, Inc. ($SYRE)
Key Points
- Driehaus Capital Management changed its Spyre Therapeutics, Inc. ($SYRE) stake by 3.2% last quarter, cutting to 2,790,785 shares worth $225.47 million.
- Wall Street's consensus rating on $SYRE is Strong Buy and an average price target of $96.07.
- $SYRE last traded around $80.79.
Driehaus Capital Management trimmed its position in Spyre Therapeutics, Inc. ($SYRE) by 3.2% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,790,785 shares of Spyre Therapeutics, Inc. after selling 91,635 shares during the quarter. Driehaus Capital Management's holdings in Spyre Therapeutics, Inc. were worth $225.47 million as of its most recent filing.
Spyre Therapeutics, Inc. ($SYRE) Stock
Spyre Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.